These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
653 related articles for article (PubMed ID: 25635866)
1. A critical dose of doxorubicin is required to alter the gene expression profiles in MCF-7 cells acquiring multidrug resistance. Tsou SH; Chen TM; Hsiao HT; Chen YH PLoS One; 2015; 10(1):e0116747. PubMed ID: 25635866 [TBL] [Abstract][Full Text] [Related]
2. Gain-of-function p53 mutant with 21-bp deletion confers susceptibility to multidrug resistance in MCF-7 cells. Tsou SH; Hou MH; Hsu LC; Chen TM; Chen YH Int J Mol Med; 2016 Jan; 37(1):233-42. PubMed ID: 26572087 [TBL] [Abstract][Full Text] [Related]
3. Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel- and adriamycin-resistant breast cancer cell lines. Li WJ; Zhong SL; Wu YJ; Xu WD; Xu JJ; Tang JH; Zhao JH Mol Biol Rep; 2013 Nov; 40(11):6143-50. PubMed ID: 24078162 [TBL] [Abstract][Full Text] [Related]
4. Molecular iodine impairs chemoresistance mechanisms, enhances doxorubicin retention and induces downregulation of the CD44+/CD24+ and E-cadherin+/vimentin+ subpopulations in MCF-7 cells resistant to low doses of doxorubicin. Bontempo A; Ugalde-Villanueva B; Delgado-González E; Rodríguez ÁL; Aceves C Oncol Rep; 2017 Nov; 38(5):2867-2876. PubMed ID: 28901484 [TBL] [Abstract][Full Text] [Related]
5. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265 [TBL] [Abstract][Full Text] [Related]
6. miR-200b regulates epithelial-mesenchymal transition of chemo-resistant breast cancer cells by targeting FN1. Yang X; Hu Q; Hu LX; Lin XR; Liu JQ; Lin X; Dinglin XX; Zeng JY; Hu H; Luo ML; Yao HR Discov Med; 2017 Sep; 24(131):75-85. PubMed ID: 28972876 [TBL] [Abstract][Full Text] [Related]
7. Reversal of P-glycoprotein-mediated multidrug resistance is induced by saikosaponin D in breast cancer MCF-7/adriamycin cells. Li C; Guan X; Xue H; Wang P; Wang M; Gai X Pathol Res Pract; 2017 Jul; 213(7):848-853. PubMed ID: 28554760 [TBL] [Abstract][Full Text] [Related]
8. Down-regulation of c-fos by shRNA sensitizes adriamycin-resistant MCF-7/ADR cells to chemotherapeutic agents via P-glycoprotein inhibition and apoptosis augmentation. Shi R; Peng H; Yuan X; Zhang X; Zhang Y; Fan D; Liu X; Xiong D J Cell Biochem; 2013 Aug; 114(8):1890-900. PubMed ID: 23494858 [TBL] [Abstract][Full Text] [Related]
9. miRNA-200c increases the sensitivity of breast cancer cells to doxorubicin through the suppression of E-cadherin-mediated PTEN/Akt signaling. Chen Y; Sun Y; Chen L; Xu X; Zhang X; Wang B; Min L; Liu W Mol Med Rep; 2013 May; 7(5):1579-84. PubMed ID: 23546450 [TBL] [Abstract][Full Text] [Related]
10. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway. Chen T; Wang C; Liu Q; Meng Q; Sun H; Huo X; Sun P; Peng J; Liu Z; Yang X; Liu K Cancer Biol Ther; 2015; 16(1):106-14. PubMed ID: 25482933 [TBL] [Abstract][Full Text] [Related]
11. Survivin transcription is associated with P-glycoprotein/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells. Liu F; Liu S; He S; Xie Z; Zu X; Jiang Y Oncol Rep; 2010 May; 23(5):1469-75. PubMed ID: 20372866 [TBL] [Abstract][Full Text] [Related]
12. Reversal effects of Rabdosia rubescens extract on multidrug resistance of MCF-7/Adr cells in vitro. Li F; Fan J; Wu Z; Liu RY; Guo L; Dong Z; Wang Z Pharm Biol; 2013 Sep; 51(9):1196-203. PubMed ID: 23777360 [TBL] [Abstract][Full Text] [Related]
13. Salinomycin reduces epithelial-mesenchymal transition-mediated multidrug resistance by modifying long noncoding RNA HOTTIP expression in gastric cancer cells. Mao Z; Wu Y; Zhou J; Xing C Anticancer Drugs; 2019 Oct; 30(9):892-899. PubMed ID: 30882398 [TBL] [Abstract][Full Text] [Related]
14. A novel anthracene derivative, MHY412, induces apoptosis in doxorubicin-resistant MCF-7/Adr human breast cancer cells through cell cycle arrest and downregulation of P-glycoprotein expression. De U; Chun P; Choi WS; Lee BM; Kim ND; Moon HR; Jung JH; Kim HS Int J Oncol; 2014 Jan; 44(1):167-76. PubMed ID: 24190517 [TBL] [Abstract][Full Text] [Related]
15. Forced expression of heat shock protein 27 (Hsp27) reverses P-glycoprotein (ABCB1)-mediated drug efflux and MDR1 gene expression in Adriamycin-resistant human breast cancer cells. Kanagasabai R; Krishnamurthy K; Druhan LJ; Ilangovan G J Biol Chem; 2011 Sep; 286(38):33289-300. PubMed ID: 21784846 [TBL] [Abstract][Full Text] [Related]
16. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism. Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644 [TBL] [Abstract][Full Text] [Related]
17. Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin. Xue C; Wang C; Sun Y; Meng Q; Liu Z; Huo X; Sun P; Sun H; Ma X; Ma X; Peng J; Liu K Oncotarget; 2017 Jan; 8(5):8622-8632. PubMed ID: 28052008 [TBL] [Abstract][Full Text] [Related]
18. Psoralen reverses the P-glycoprotein-mediated multidrug resistance in human breast cancer MCF-7/ADR cells. Jiang J; Wang X; Cheng K; Zhao W; Hua Y; Xu C; Yang Z Mol Med Rep; 2016 Jun; 13(6):4745-50. PubMed ID: 27082231 [TBL] [Abstract][Full Text] [Related]
19. Co-ordinate loss of protein kinase C and multidrug resistance gene expression in revertant MCF-7/Adr breast carcinoma cells. Budworth J; Gant TW; Gescher A Br J Cancer; 1997; 75(9):1330-5. PubMed ID: 9155054 [TBL] [Abstract][Full Text] [Related]
20. Downregulation of GSTpi expression by tryptanthrin contributing to sensitization of doxorubicin-resistant MCF-7 cells through c-jun NH2-terminal kinase-mediated apoptosis. Yu ST; Chen TM; Chern JW; Tseng SY; Chen YH Anticancer Drugs; 2009 Jun; 20(5):382-8. PubMed ID: 19318911 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]